Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.39 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.39 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.39 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.39 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14324924 | 0.81 | CCNA2 (0.52) | MAPK1 | |
| SCHEMBL4421326 | 0.77 | LMNA (0.42) | RAB9AL3MBTL1LMNAPOLB | |
| SCHEMBL1863655 | 0.75 | ATM (0.57) | DEGS1RAB9ANPC1GLAMAPK1 | |
| SCHEMBL1863837 | 0.75 | ATM (0.57) | DEGS1RAB9ANPC1GLAMAPK1 | |
| SCHEMBL13914963 | 0.75 | GAA (0.62) | DEGS1RAB9ANPC1GLAMAPK1 | |
| SCHEMBL16596335 | 0.74 | DEGS1 (0.51) | DEGS1RAB9ANPC1GLAMAPK1 | |
| SCHEMBL14255022 | 0.73 | HDAC4 (0.62) | — | |
| SCHEMBL18328436 | 0.72 | HPGD (0.62) | RAB9ALMNAPOLBSOAT2SOAT1 | |
| SCHEMBL18328433 | 0.72 | LMNA (0.49) | DEGS1RAB9ANPC1GLAMAPK1 | |
| SCHEMBL1868251 | 0.72 | PKM (0.57) | DEGS1RAB9ANPC1GLAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280034-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20100280034-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-7338969-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338969-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070208012-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-09-06 | — | — | US | disclosed |
| US-20070208012-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-09-06 | — | — | US | disclosed |
| US-20070203128-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070203128-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070196340-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070197492-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070197492-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070196340-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070184014-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-09 | — | — | US | disclosed |
| US-20070184014-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-09 | — | — | US | disclosed |
| US-20070093534-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-04-26 | — | — | US | disclosed |
| US-20070093534-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197492-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | DEGS1 1086/4885RAB9A 1224/4885NPC1 3826/4885 |
| US-20070203128-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | DEGS1 1086/4885RAB9A 1224/4885NPC1 3826/4885 |
| US-20070093534-A1 | Modulation of Pathogenicity | NR1H4, NR1I3, NR1H2 | DEGS1 1029/4885RAB9A 1938/4885NPC1 675/4885 |
| US-20070208012-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | DEGS1 1086/4885RAB9A 1224/4885NPC1 3826/4885 |
| US-20100280034-A1 | Modulation of pathogenicity | NR1H4, NR1I3, NR1H2 | DEGS1 1029/4885RAB9A 1938/4885NPC1 675/4885 |
| US-20070184014-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | DEGS1 1086/4885RAB9A 1224/4885NPC1 3826/4885 |
| US-20070196340-A1 | Modulation of Pathogenicity | NR1H4, NR1I3, NR1H2 | DEGS1 1029/4885RAB9A 1938/4885NPC1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.